NASDAQ:ZBIO Zenas Biopharma (ZBIO) Stock Price, News & Analysis $10.10 +0.04 (+0.40%) As of 11:46 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas Biopharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas Biopharma alerts:Sign Up Key Stats Today's Range$9.71▼$10.3250-Day Range$6.77▼$11.9252-Week Range$5.83▼$26.25Volume53,636 shsAverage Volume181,665 shsMarket Capitalization$422.52 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company OverviewZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.Read More… Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO Stock News HeadlinesSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 2 at 1:26 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 2 at 12:04 PM | globenewswire.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.June 3, 2025 | Altimetry (Ad)ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 2 at 9:10 AM | prnewswire.comZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitJune 2 at 4:00 AM | prnewswire.comZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIOJune 2 at 4:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 1 at 10:00 AM | prnewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIOJune 1 at 8:41 AM | globenewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas Biopharma's stock was trading at $7.90 at the beginning of 2025. Since then, ZBIO stock has increased by 27.3% and is now trading at $10.06. View the best growth stocks for 2025 here. How were Zenas Biopharma's earnings last quarter? Zenas Biopharma Inc (NASDAQ:ZBIO) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The company earned $10 million during the quarter, compared to analysts' expectations of $5 million. When did Zenas Biopharma IPO? Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. Who are Zenas Biopharma's major shareholders? Top institutional investors of Zenas Biopharma include Wellington Management Group LLP (2.09%), Charles Schwab Investment Management Inc. (0.28%), Jefferies Financial Group Inc. (0.11%) and Nuveen LLC (0.08%). How do I buy shares of Zenas Biopharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings5/15/2025Today6/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$45.00 Low Stock Price Target$30.00 Potential Upside/Downside+264.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$15 million Price / Sales28.06 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares41,834,000Free FloatN/AMarket Cap$420.85 million OptionableN/A BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.